Medication info
Metgreen SR Tablet 500mg (Metformin Hydrochloride)

Metgreen SR Tablet 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Green Cross Corporation
Appearance
White or light yellow, biconvex, rectangular film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200502773 · Approved 2005.11.11 · Insurance code 643601030

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on the therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted accordingly. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week. The dose may be increased to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider taking 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. - During initiation of treatment and dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment at stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Green Cross Corporation

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes whose blood sugar control is not sufficient by diet and exercise alone, particularly in those who are overweight. It can be used alone or in combination with other oral hypoglycemic agents or insulin to effectively control blood sugar. This contributes to the health improvement of those who have difficulty managing their blood sugar.

How to take

Adult dose

The dose should be determined individually based on the therapeutic response and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted accordingly. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week. The dose may be increased to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider taking 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg of immediate-release metformin tablets per day. - During initiation of treatment and dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment at stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause severe lactic acidosis which can be life-threatening, so patients should be cautious of symptoms of lactic acidosis while taking this medication. In addition, hypoglycemia may occur when taken in conjunction with insulin or sulfonylurea medications, so blood sugar levels should be closely monitored. Patients with moderate to severe renal impairment, dehydration, severe infections, or acute illnesses affecting renal function such as acute myocardial infarction should not use this medication. Patients with acute and unstable heart failure should also avoid taking this medication, and it should be discontinued for a certain period before and after examinations using iodinated contrast media. Patients who are allergic to this medication or to biguanides, patients with type 1 diabetes, and those with a history of lactic acidosis or diabetic ketoacidosis should also avoid its use. Patients with severe infections, trauma, pre- and post-surgery, malnutrition, hepatic impairment, severe respiratory failure, and those who consume excessive alcohol should also suspend or use this medication with caution. While taking this medication, gastrointestinal disorders, taste disturbances, and vitamin B12 deficiency may occur, so patients should consult a doctor if symptoms are severe. Renal function should be monitored regularly to ensure the safe use of this medication, and particular caution is needed for elderly patients or those with reduced renal function. Hypoglycemia may occur, so blood sugar levels should be carefully managed in situations of irregular meals, vigorous exercise, or in combination with other hypoglycemic agents. Alcohol consumption can increase the risk of lactic acidosis, so it is advisable not to indulge in excessive drinking while taking this medication. Patients who are pregnant or breastfeeding should consult a physician before taking this medication, as it may affect the fetus and newborn. This medication is not recommended for children, and elderly patients may need appropriate dosage adjustments based on renal function. In case of overdose, hypoglycemia is rare, but there is a risk of lactic acidosis, and immediate medical attention should be sought for appropriate treatment. This medication may interact with other drugs, so patients should inform healthcare providers of any medications they are taking, and should consult immediately if there are changes in blood sugar levels or abnormal symptoms. Finally, this medication should be swallowed whole, and it is normal for the tablet coating to be excreted, so there is no need for concern.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. Additionally, it is best to keep the medication at room temperature between 1 to 30 degrees Celsius, avoiding extremely hot or cold environments.

Appearance and packaging

Appearance

White or light yellow, biconvex, rectangular film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.